<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972946</url>
  </required_header>
  <id_info>
    <org_study_id>2007/R/CAR/15.2</org_study_id>
    <nct_id>NCT00972946</nct_id>
  </id_info>
  <brief_title>Cell Tracking Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI) - A Pilot Study</brief_title>
  <official_title>The Use of Magnetic Resonance Imaging and Superparamagnetic Particles of Iron Oxide in Cardiovascular Disease - a Pilot Study in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal College of Surgeons of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Medicine Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ability to label specific cells and image their natural movements in vivo would allow&#xD;
      researchers to investigate the mechanisms of disease progression. In addition, cell-based&#xD;
      therapy, especially stem cell therapy, requires non-invasive monitoring of transplanted cells&#xD;
      to follow their bio-distribution and biological function. Because of recent interest in stem&#xD;
      cell treatment, several methods have been investigated for in vivo cell tracking. The&#xD;
      investigators propose to assess whether the magnetic resonance imaging (MRI) contrast agent&#xD;
      Endorem (superparamagnetic particles of iron oxide) can be used to label cells for in vivo&#xD;
      tracking using MRI. The investigators will use 20 healthy human volunteers to:&#xD;
&#xD;
        1. Assess the feasibility of imaging Endorem-labelled cells in vivo&#xD;
&#xD;
        2. Compare the distribution of Endorem-labelled cells with that of intravenous injection of&#xD;
           Endorem&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">January 6, 2012</completion_date>
  <primary_completion_date type="Actual">January 6, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in signal intensity in the region of interest on MRI scanning</measure>
    <time_frame>0 hours, 24 hours, 48 hours, 5-7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Administration of labelled cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI scanning before and after administration of iron-labelled cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of Endorem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI scanning before and after intravenous administration of Endorem</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Administration of autologous Endorem-labelled mononuclear cells intravenously</intervention_name>
    <description>single dose</description>
    <arm_group_label>Administration of labelled cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of Endorem</intervention_name>
    <description>single dose, intravenous</description>
    <arm_group_label>Administration of Endorem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Contraindication to MRI scanning (detected by safety questionnaire) including severe&#xD;
             claustrophobia&#xD;
&#xD;
          -  Inability or refusal to give informed consent&#xD;
&#xD;
          -  Renal or hepatic dysfunction&#xD;
&#xD;
          -  HIV/hepatitis B/ hepatitis C/ HTLV/ syphilis&#xD;
&#xD;
          -  Intercurrent illness&#xD;
&#xD;
          -  Blood dyscrasias&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Newby</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Edinburgh/Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, Gray C, Crawford JH, Alam SR, Atkinson AP, Forrest EK, Bienek C, Mills NL, Burdess A, Dhaliwal K, Simpson AJ, Wallace WA, Hill AT, Roddie PH, McKillop G, Connolly TA, Feuerstein GZ, Barclay GR, Turner ML, Newby DE. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circ Cardiovasc Imaging. 2012 Jul;5(4):509-17. doi: 10.1161/CIRCIMAGING.112.972596. Epub 2012 Jul 10.</citation>
    <PMID>22787016</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 7, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>SPIO</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

